Literature DB >> 10178663

The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?

C Donaldson1.   

Abstract

There has been much recent debate in the health economics literature as to the (near) equivalence of cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA). The aim of this paper is to demonstrate that whether such a (near) equivalence exists depends on whether one defines economic evaluations as 'CBA' or 'CEA' on the basis of either what is measured or what question the analyst is seeking to answer. The former basis of definition is popular within the 'decision science' approach to economic evaluation, but does not seem to have any theoretical support. If the latter, more theoretically correct, basis is accepted, there is no longer a case for the (near) equivalence of CBA and CEA.

Mesh:

Year:  1998        PMID: 10178663     DOI: 10.2165/00019053-199813040-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  21 in total

1.  Assessment of health producing measures across different sectors.

Authors:  M Drummond; G Stoddart
Journal:  Health Policy       Date:  1995-09       Impact factor: 2.980

2.  Accounting for future costs in medical cost-effectiveness analysis.

Authors:  D Meltzer
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

3.  Assessing community values in health care: is the 'willingness to pay' method feasible?

Authors:  C Donaldson; S Farrar; T Mapp; A Walker; S Macphee
Journal:  Health Care Anal       Date:  1997-03

Review 4.  Cost-effectiveness ratios: in a league of their own.

Authors:  S Birch; A Gafni
Journal:  Health Policy       Date:  1994-05       Impact factor: 2.980

Review 5.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

6.  Applications of cost-benefit analysis to health care. Departures from welfare economic theory.

Authors:  S Birch; C Donaldson
Journal:  J Health Econ       Date:  1987-09       Impact factor: 3.883

7.  Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?

Authors:  I S Kristiansen; A E Eggen; D S Thelle
Journal:  BMJ       Date:  1991-05-11

8.  Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.

Authors:  W McGuire; A I Neugut; S Arikian; J Doyle; C M Dezii
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

9.  Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.

Authors:  L M Elit; A Gafni; M N Levine
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

10.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

Authors:  D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

View more
  6 in total

Review 1.  Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science.

Authors:  E McIntosh; C Donaldson; M Ryan
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

2.  Health economic evaluation.

Authors:  A Shiell; C Donaldson; C Mitton; G Currie
Journal:  J Epidemiol Community Health       Date:  2002-02       Impact factor: 3.710

3.  Economics of public health programs for underserved populations: a review of economic analysis of the National Breast and Cervical Cancer Early Detection Program.

Authors:  Jaya S Khushalani; Justin G Trogdon; Donatus U Ekwueme; K Robin Yabroff
Journal:  Cancer Causes Control       Date:  2019-10-09       Impact factor: 2.506

Review 4.  The potential to forgo social welfare gains through overrelianceon cost effectiveness/cost utility analyses in the evidence base for public health.

Authors:  D R Cohen; N Patel
Journal:  J Environ Public Health       Date:  2009-12-02

Review 5.  Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?

Authors:  James Buchanan; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

Review 6.  Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?

Authors:  Anthony J Culyer; Kalipso Chalkidou
Journal:  Value Health       Date:  2018-07-26       Impact factor: 5.725

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.